journal article·2021-02

Oxygen-independent free radical generation mediated by core-shell magnetic nanocomposites synergizes with immune checkpoint blockade for effective primary and metastatic tumor treatment

Jin-Cheng Guo, Qiao An, Mengyu Guo, Yating Xiao, Bo Li, Fene Gao, Yuqing Wang, Jiayang Li, Yaling Wang, Ying Liu, Huan Meng, Jia Guo, Jing Liu

Nano Today· Volume 36
Publisher page

Abstract

Abstract Advanced or metastatic tumor treatment is a long-lasting problem that leads to high mortality. Photodynamic therapy (PDT) has emerged as a promising clinical therapeutic strategy with the ability of destroying local tumors and initiating systemic anti-tumor immune responses for metastasis inhibition. However, the efficacy is typically limited by tumor hypoxia, aggregation caused self-quenching of classic photosensitizers (PSs), and intrinsic or adaptive immune resistance that mediated by cellular and molecular immunosuppressive components. Here, we designed an oxygen-independent photosensitizer by core-shell magnetic nanocomposites (MNCs), with functionalized iron oxide nanoclusters as the core and coordination polymerization of Zinc Tetra (N-methyl-4-pyridyl) porphyrin (ZnTMPyP) as the shell. MNCs PDT induced persistent free radical generation via facilitating an effective electron-hole separation, polarized macrophages to pro-inflammatory M1 phenotype, and activated systemic antitumor immunity. Nevertheless, adaptive immune resistance occurred simultaneously, characterized by highly increased PD-L1 expression on tumor cells, dendritic cells (DCs) and macrophages. As a result, combined use of MNCs PDT with checkpoint blockade effectively suppressed well-established primary tumors as well as tumor metastasis via a ‘trident’ modality, including persistent free radical generation in both normoxic and hypoxic conditions for direct tumor destruction, enhanced frequency of tumor infiltrating-lymphocytes (TILs) and modified tumor immunosuppressive microenvironment with reduced immunosuppressive cells and PD-L1 blockade. We also explore the underlying mechanisms of metastasis inhibition according to the transcriptome expression profiling of lung tissues, which revealed that the ‘trident’ modality altered numerous genes mainly related to immuno-activation and cancer associated signaling pathways. We expect the expanded use of this platform for various types of cancer malignancy.
Source: openaire · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Immune cells in cancer · Cancer, Hypoxia, and Metabolism

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (46)

Show source-provided references
1. Schroeder · Nat. Rev. Cancer · 2012 · 12 · 3910.1038/nrc3180 ↗
2. Fesnak · Nat. Rev. Cancer · 2016 · 16 · 56610.1038/nrc.2016.97 ↗
3. Yang · J. Clin. Invest. · 2015 · 125 · 333510.1172/JCI83871 ↗
4. Chen · Chem. Soc. Rev. · 2019 · 48 · 550610.1039/C9CS00271E ↗
5. Lu · Nat. Commun. · 2017 · 8
6. Kuai · Sci. Adv. · 2018 · 410.1126/sciadv.aao1736 ↗
7. Wang · Nano Lett. · 2019 · 19 · 526610.1021/acs.nanolett.9b01717 ↗
8. Chao · Nat. Biomed. Eng. · 2018 · 2 · 611-+10.1038/s41551-018-0262-6 ↗
9. Ni · Nat. Commun. · 2018 · 9
10. Chen · Nat. Commun. · 2016 · 7
11. Song · ACS Nano · 2018 · 12 · 197810.1021/acsnano.7b09112 ↗
12. Yu · ACS Nano · 2017 · 11 · 1014710.1021/acsnano.7b04736 ↗
13. Wang · Nano Lett. · 2016 · 16 · 550310.1021/acs.nanolett.6b01994 ↗
14. He · Nat. Commun. · 2016 · 7
15. Duan · J. Am. Chem. Soc. · 2016 · 138 · 1668610.1021/jacs.6b09538 ↗
16. Lu · J. Am. Chem. Soc. · 2016 · 138 · 1250210.1021/jacs.6b06663 ↗
17. Ji · Angew. Chem. Int. Ed. · 2018 · 57 · 1138410.1002/anie.201807602 ↗
18. Cai · Angew. Chem. Int. Ed. · 2020 · 59 · 1401410.1002/anie.202001107 ↗
19. Liu · Adv. Mater. · 2018 · 30
20. Cheng · Nat. Commun. · 2015 · 6
21. Yang · Nat. Commun. · 2017 · 8
22. Fan · Adv. Mater. · 2015 · 27 · 415510.1002/adma.201405141 ↗
23. Wang · Sci. Transl. Med. · 2018 · 10
24. Pollard · Nat. Rev. Cancer · 2004 · 4 · 7110.1038/nrc1256 ↗
25. Biswas · Nat. Immunol. · 2010 · 11 · 88910.1038/ni.1937 ↗
26. Noy · Immunity · 2014 · 41 · 4910.1016/j.immuni.2014.06.010 ↗
27. Nishikawa · Curr. Opin. Immunol. · 2014 · 27 · 110.1016/j.coi.2013.12.005 ↗
28. Zou · Nat. Rev. Immunol. · 2006 · 6 · 29510.1038/nri1806 ↗
29. Togashi · Immunity · 2017 · 41 · 3
30. Buchbinder · Nat. Rev. Clin. Oncol. · 2016 · 13 · 7710.1038/nrclinonc.2015.237 ↗
31. Errico · Nat. Rev. Clin. Oncol. · 2015 · 12 · 6310.1038/nrclinonc.2014.221 ↗
32. Xu · ACS Nano · 2017 · 11 · 446310.1021/acsnano.7b00715 ↗
33. Zanganeh · Nat. Nanotechnol. · 2016 · 11 · 98610.1038/nnano.2016.168 ↗
34. An · ACS Appl. Mater. Inter. · 2013 · 5 · 1324810.1021/am4042367 ↗
35. An · Small · 2015 · 11 · 567510.1002/smll.201501491 ↗
36. Bhattacharjee · Biochimie · 2011 · 93 · 129710.1016/j.biochi.2011.05.038 ↗
37. Mandai · Clin. Cancer Res. · 2016 · 22 · 232910.1158/1078-0432.CCR-16-0224 ↗
38. Wandel · Cell Host Microbe · 2017 · 22 · 50710.1016/j.chom.2017.09.007 ↗
39. Man · J. Leukoc. Biol. Suppl. · 2017 · 101 · 14310.1189/jlb.4MR0516-223R ↗
40. Kim · Science · 2011 · 332 · 71710.1126/science.1201711 ↗
41. Mustafa · Acta Neuropathol. · 2018 · 135 · 58110.1007/s00401-018-1806-2 ↗
42. Zhang · Cell Death Dis. · 2017 · 8 · e315110.1038/cddis.2017.559 ↗
43. Stebbing · Oncogene · 2015 · 34 · 210310.1038/onc.2014.129 ↗
44. Thomsen · Cell Death Differ. · 2015 · 22 · 57410.1038/cdd.2014.213 ↗
45. Lee · Chem. Soc. Rev. · 2012 · 41 · 257510.1039/C1CS15248C ↗
46. Rastinehad · Proc. Natl. Acad. Sci. U. S. A. · 2019 · 116 · 1859010.1073/pnas.1906929116 ↗